Substudy : Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (EXA)

Laval University

Status: Unknown

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Other: No specific intervention for this study

Study type: Observational

Funder types: Other

Identifiers

NCT02282436

EXA-COPD-20765

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Its prevalence is in progression and COPD is expected to become the fourth leading cause of death by 2030. COPD is characterized by periods of stability interspersed with acute infectious/inflammatory flare-ups, also called acute exacerbations, during which patients deteriorate, sometimes to the point of requiring immediate medical assistance. Although most patients eventually recover, repeated episodes of exacerbations may accelerate COPD progression. Exacerbations may further compromise the integrity of limb muscles by promoting further loss in muscle mass and strength.

The overall objective of this substudy is to elucidate how an acute COPD exacerbation may affect limb muscles.

Full description

Focusing our attention during exacerbations, a period of aggravated systemic inflammation, should be more rewarding in terms of understanding the link between inflammation burst and muscle disease in COPD. We have recently acquired experimental data supporting a role for the ubiquitin proteasome pathway in the worsening of limb muscle structure and function during an acute exacerbation, providing a solid framework for this investigation. The overall objective of this proposal is to substantiate these preliminary findings and elucidate how systemic inflammation during acute COPD exacerbation may affect limb muscles. Ultimately, our research could open new therapeutic avenues to minimize the systemic consequences of an acute exacerbation.

Enrollment: 20 estimated patients

Sex: All

Ages: 50 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• male and female
• COPD with an FEV1 of under 60% of predicted
• non-smoker
• between 50 and 75 years old
• experiencing an acute exacerbation of COPD (24-48 hours, before treatment)

Exclusion criteria

• all inflammatory disease (HIV, cancer, renal and cardiac deficiency)
• hormonal dysregulation
• inferior limb pathology
• neuromuscular pathology
• history of tobacco or alcool abuse
• oxygen dependent

Trial design

20 participants in 1 patient group

COPD exacerbation

Description:

No specific intervention for this study

Treatment:

Other: No specific intervention for this study